Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Therapeutic effect of adipose-derived mesenchymal stem cells in a porcine model of abdominal sepsis.

Vélez-Pinto JF., Garcia-Arranz M., García-Bernal D., García Gómez-Heras S., Villarejo-Campos P., García-Hernández AM.

Prospective Study on Immune Modulation, published in Stem Cell Res Ther (2023) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Stem Cell Res Ther (2023)
Country
England
Reported sample size
—
Source database
PubMed
PMID
38087374
PMCID
PMC10717819
DOI
10.1186/s13287-023-03588-x
Citations
3

Abstract (original English)

Background The term sepsis refers to a complex and heterogeneous syndrome. Although great progress has been made in improving the diagnosis and treatment of this condition, it continues to have a huge impact on morbidity and mortality worldwide. Mesenchymal stem cells are a population of multipotent cells that have immunomodulatory properties, anti-apoptotic effects, and antimicrobial activity. We studied these capacities in a porcine model of peritoneal sepsis. Methods We infused human adipose-derived mesenchymal stem cells (ADSCs) into a porcine model of peritoneal sepsis. Twenty piglets were treated with antibiotics alone (control group) or antibiotics plus peritoneal infusion of ADSCs at a concentration of 2 × 10 6 cells/kg or 4 × 10 6 cells/kg (low- and high-dose experimental groups, respectively). The animals were evaluated at different time points to determine their clinical status, biochemical and hematologic parameters, presence of inflammatory cytokines and chemokines in blood and peritoneal fluid, and finally by histologic analysis of the organs of the peritoneal cavity. Results One day after sepsis induction, all animals presented peritonitis with bacterial infection as well as elevated C-reactive protein, haptoglobin, IL-1Ra, IL-6, and IL-1b. Xenogeneic ADSC infusion did not elicit an immune response, and peritoneal administration of the treatment was safe and feas

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansAnimalsSwineInterleukin 1 Receptor Antagonist ProteinInterleukin-6Mesenchymal Stem CellsPeritonitisSepsisAnti-Bacterial Agents

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research